Baidu
map

Spine:研究发现勃起功能障碍与处方类止痛药相关

2013-05-21 climb-climb MedSci原创

MedSci导读:今天在网络版Spine杂志公布的一项研究表明,长期使用阿片肽使获得ED处方的可能性增加50%。最常用的阿片类处方药物是氢可酮,羟考酮和吗啡。研究人员定义“长期”的时间是使用阿片肽服用10片或更多至少4个月或者超过3个月。   两年前,在泌尿学杂志发表的一项研究表明,经常服用非处方非激素类抗炎药物如阿司匹林,布洛芬和萘普生的男性比较少服用或未服用此类药物的男性更

MedSci导读:今天在网络版Spine杂志公布的一项研究表明,长期使用阿片肽使获得ED处方的可能性增加50%。最常用的阿片类处方药物是氢可酮,羟考酮和吗啡。研究人员定义“长期”的时间是使用阿片肽服用10片或更多至少4个月或者超过3个月。


  两年前,在泌尿学杂志发表的一项研究表明,经常服用非处方非激素类抗炎药物如阿司匹林,布洛芬和萘普生的男性比较少服用或未服用此类药物的男性更有可能有勃起问题。
  现在,对于在痛苦中的男性来说,更多潜在的坏消息是:今天在网络版Spine杂志公布的一项研究表明,勃起功能障碍可能与处方类止痛药(阿片类)相关。
  最常用的阿片类处方药物是氢可酮,羟考酮和吗啡。
  研究人员研究了11,327人的案例,他们都是加入俄勒冈州和华盛顿Kaiser Permanente健康计划,在2004年因背部疼痛看过医生的。研究者查看了患者背部疼痛前后六个月的药房记录,以了解记录上是否填满了阿片类处方药和睾酮替代品或勃起功能障碍,ED,药物治疗。
  他们发现,长期使用阿片肽使获得ED处方的可能性增加50%。研究人员定义“长期”的时间是使用阿片肽服用10片或更多至少4个月或者超过3个月。
  服用大量阿片类药物至少4个月的男性,19%以上也收到睾酮替代品或ED药物。少于7%的患者未使用阿片类药物而收到ED药物。
  “这并不意味着这些药物引起了ED,” 这项研究的第一作者Richard A. Deyo博士说,“但是这些联系是患者和临床医生在决定阿片类药物是否用于治疗背部疼痛时应该注意的。”
Deyo是Kaiser Permanente健康研究中心的研究员和俄勒冈健康与科学大学的循证家庭医学教授。

Prescription painkillers, erectile dysfunction linked, Kaiser Permanente researchers find
Two years ago, a study published in The Journal of Urology indicated that men routinely taking such over-the-counter nonsteroidal anti-inflammatory drugs as aspirin, ibuprofen and naproxen were more likely to have erection problems than men who took the drugs less often or not at all.
Now, more potentially bad news for men in pain: A study published online today in the journal Spine indicates erectile dysfunction may be linked to prescription painkillers known as opiods.
The most commonly prescribed opiods are hydrocodone, oxycodone and morphine.
Researchers studied the records of 11,327 men in Oregon and Washington enrolled in the Kaiser Permanente health plan who had visited their doctors for back pain in 2004. Investigators looked at the patients' pharmacy records for six months before and after the back-pain visit to learn whether they'd filled prescriptions for opiods and for testosterone replacement or erectile dysfunction, or ED, medications.
They found that long-term opiod use increased by 50 percent the likelihood of also getting an ED prescription. Researchers defined long-term as men who took opiods for at least four months or for more than three months with 10 or more refills.
More than 19 percent of men who took high-dose opiods for at least four months also received testosterone replacement or ED drugs; fewer than 7 percent of men who did not take opiods received ED drugs.
"This doesn't mean that these medications cause ED," said Dr. Richard A. Deyo, the study's lead author, "but the association is something patients and clinicians should be aware of when deciding if opiods should be used to treat back pain."
Deyo is an investigator with the Kaiser Permanente Center for Health Research and a professor of evidence-based family medicine at Oregon Health & Science University.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
    2013-06-18 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
    2014-01-13 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1699246, encodeId=7003169924617, content=<a href='/topic/show?id=f5821661e14' target=_blank style='color:#2F92EE;'>#Spine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16617, encryptionId=f5821661e14, topicName=Spine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba5829925263, createdName=mgqwxj, createdTime=Tue Jun 18 11:49:00 CST 2013, time=2013-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771113, encodeId=c46c1e7111325, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Mon Jan 13 11:49:00 CST 2014, time=2014-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289934, encodeId=41e4128993433, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405480, encodeId=c87b14054801f, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420983, encodeId=2e4d142098310, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502697, encodeId=be0c150269ee3, content=<a href='/topic/show?id=bf0f3342395' target=_blank style='color:#2F92EE;'>#勃起功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33423, encryptionId=bf0f3342395, topicName=勃起功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e529549448, createdName=liuyiping, createdTime=Thu May 23 05:49:00 CST 2013, time=2013-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753000, encodeId=bbd61e5300027, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Jun 13 16:49:00 CST 2013, time=2013-06-13, status=1, ipAttribution=)]

相关资讯

AUA2013:75%勃起障碍患者未接受治疗

  圣迭戈——伊利诺伊州北岸大学医学院的Brian T. Helfand医生在美国泌尿外科学会(AUA)2013年会上报告,在获得ICD-9勃起功能障碍诊断的男性患者中,仅有25%接受了针对这一疾病的治疗。   Helfand医生及其合作者使用IMS的数据集,识别出在截至2011年7月的12个月内获得ICD-9勃起功能障碍(ED)诊断的6,228,509例年龄超过30岁的男性患者。IMS是一个大

美食品药监局批准Stendra用于治疗勃起功能障碍

美国食品和药物管理局27日批准治疗勃起功能障碍的新药Stendra(阿伐那非)。 勃起功能障碍是指男性无法勃起或维持勃起困难。估计美国有30万男性受到勃起功能障碍的影响。 Stendra是口服制剂可根据需要在患者性活动30分钟前服用。医生应按Stendra起效规定的最低剂量处方。 “此批准扩大现有治疗男性勃起功能障碍方案的选择,使患者通过向医生咨询选择他们需要的最适当的治疗。”,FDA药物评

Baidu
map
Baidu
map
Baidu
map